Klotho Neurosciences to Acquire Turn Biotechnologies' Select Assets for $300 Million Global Pharma Partnership

Klotho Neurosciences has signed a Letter of Intent to acquire select assets from Turn Biotechnologies, including the ERA platform and eTurna RNA delivery system. The proposed transaction would position Klotho as a leader in longevity therapeutics and is subject to completion of due diligence and customary closing conditions. A signed out-licensing and co-development partnership with a South Korean pharmaceutical company worth up to $300 million is also part of the deal.

Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biotechnology company focused on longevity therapeutics, has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. The proposed transaction includes Turn's ERA platform and eTurna RNA delivery system, positioning Klotho as a leader in the development of longevity therapeutics Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership^[1].

The ERA platform and eTurna RNA delivery system are designed to rejuvenate somatic cells and restore tissue function, creating opportunities for regenerative therapies in various fields, including dermatology, ophthalmology, immunology, osteoarthritis, muscle health, and diseases like amyotrophic lateral sclerosis (ALS) Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership^[1]. The acquisition is subject to completion of due diligence, execution of a definitive agreement, and customary closing conditions.

In addition to the acquisition, Klotho will also acquire a signed out-licensing and co-development partnership with a South Korean pharmaceutical company worth up to $300 million. This partnership underscores the commercial interest in Turn's platform and highlights the broad potential applications of its technology Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership^[1].

"This LOI marks a transformative step for Klotho," said Dr. Joseph Sinkule, CEO of Klotho Neurosciences. "By adding Turn's ERA technology, which leverages six RNA molecules, including four of the Yamanaka transcription factors that can reset cellular age, together with the eTurna RNA lipid nanoparticle (LNP) delivery platform, we are expanding beyond a single Klotho gene into a powerful system of cellular rejuvenation" Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership^[1].

Upon completion of the contemplated transaction, Klotho plans to rebrand to reflect its broadened mission and expanded therapeutic reach. Klotho also intends to bring over key members of Turn's management and R&D teams post-close.

The longevity medicine market is one of the fastest-growing global sectors. The world's aging population is expected to hit 2.1 billion by 2050, driving healthcare costs already at 10% of global GDP and projected to exceed $47 trillion by 2030. Klotho aims to lead this transformation by addressing aging at its root cause — the cell Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership^[1].